<DOC>
	<DOCNO>NCT01526746</DOCNO>
	<brief_summary>The purpose research study understand whether difference amount tasimelteon ( include breakdown product ) blood individual severe renal impairment compare individual normal renal function . The safety tolerability tasimelteon also assess throughout study .</brief_summary>
	<brief_title>Pharmacokinetics Tasimelteon Subjects With Renal Impairment Matched Control Subjects With Relatively Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Groups 13 1 . Ability acceptance provide write informed consent ; 2 . Men woman 18 79 year , inclusive ; 3 . Subjects Body Mass Index ( BMI ) &gt; 18 &lt; 40 kg/m2 ( BMI = weight ( kg ) / [ height ( ) ] 2 ) ; 4 . Males , nonfecund female ( i.e. , surgically sterilize , procedure do 6 month screen subject postmenopausal , without menses 6 month screen ) , females childbearing potential use acceptable method birth control period 35 day first dose negative pregnancy test screen baseline visit ; Note 1 : Acceptable method birth control include one following : abstinence , vasectomize sexual partner , hormonal method ( i.e . pill , hormonal IUD , DepoProvera , implant , patch , intravaginal device [ NuvaRing ] ) , intrauterine device ( IUD [ copper band coil ] ) , diaphragm , cervical cap , condom spermicidal jelly foam . 5 . Willing able comply study requirement restriction ; Groups 1 2 ( renal impairment ) 1 . Subjects renal impairment define 1 . Group 1 : Stage 5 End Stage Renal Disease ( ESRD ) ( eGFR &lt; 15 mL/min/m2 ) require regularly schedule dialysis stable dialysis regimen least three month baseline ; OR 2 . Group 2 : Stage 4 severe renal impairment ( eGFR ≤ 29 mL/min/m2 ) require dialysis calculate use Modification Diet Renal Disease ( MDRD ) Equation ( Appendix 18.3 ) 2 . Otherwise consider healthy general determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen ; 3 . Vital sign ( 3 minute rest semisupine position ) within range show . 1 . Body temperature 35.037.5 °C ; 2 . Systolic blood pressure 100180 mmHg ; 3 . Diastolic blood pressure 60115 mmHg ; 4 . Pulse rate 40100 bpm . Group 3 ( healthy match control ) 1 . Subjects Group 3 must match gender , smoke status , age ( ±10 year ) , body mass index [ normal BMIs ( 18.0024.99 ) , overweight BMIs ( 25.0030.99 ) obese BMIs ( 31.0040.00 ) ] Group 1 and/or 2 ; 2 . Subjects must normal renal function define eGFR ≥ 80 mL/min/m2 calculate use Modification Diet Renal Disease ( MDRD ) Equation ( Appendix 18.3 ) ; 3 . Subjects must good health determine past medical history , physical examination , electrocardiogram , laboratory test urinalysis ; 4 . Vital sign ( 3 minute rest semisupine position ) within range show : 1 . Body temperature 35.0 37.5 °C ; 2 . Systolic blood pressure 90 150 mmHg ; 3 . Diastolic blood pressure 50 95 mmHg ; 4 . Pulse rate 40 90 bpm . Groups 13 1 . Smokers ( use tobacco product previous 3 month ) unable unwilling limit consumption 10 cigarette per day le checked inpatient facility . . Note : Smoking match criterion site attempt enroll equal number smoker nonsmoker group . 2 . Exposure investigation drug , include placebo , within 30 day 5 halflives ( whichever longer ) dosing ; 3 . Donation loss 400 mL blood within two month prior dose ; 4 . Significant illness within two week prior dose ; 5 . Answer 'yes ' either Question 4 ( Active Suicidal Ideation Some Intent Act , Without Specific Plan ) Question 5 ( Active Suicidal Ideation Specific Plan Intent ) `` Suicidal Ideation '' portion CSSRS , answer `` yes '' suiciderelated behavior ( actual attempt , interrupt attempt , abort attempt , preparatory act , behavior ) `` Suicidal Behavior '' portion Columbia Suicide Severity Rating Scale ( CSSRS ) ; ideation behavior occur within past 6 month ; 6 . Functioning renal transplant ; 7 . History within past 2 year clinically significant acute chronic bronchospastic disease , include asthma chronic obstructive pulmonary disease , treat treat ; 8 . Treatment drug know cause major organ system toxicity ( e.g. , chloramphenicol tamoxifen ) 60 day precede Screening visit ; 9 . Participation previous BMS214778/VEC162 trial ; 10 . History drug alcohol abuse define DSMIV , Diagnostic Criteria Drug Alcohol Abuse , within 12 month prior screen evidence abuse indicate laboratory assay conduct screen baseline visit . A positive drug screen Groups 1 2 acceptable documentation subject prescribe corresponding medication ; 11 . History immunocompromise , include positive HIV ( ELISA Western blot ) test result ; 12 . A positive Hepatitis B surface antigen ( HBsAg ) test result ; 13 . Any surgical medical condition might significantly alter absorption , distribution excretion drug . The Investigator guide evidence following : 1 . History clinically significant inflammatory bowel syndrome , gastritis , ulcer , gastrointestinal rectal bleeding ; 2 . History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; 3 . History pancreatic injury pancreatitis ; 4 . History presence liver disease liver injury indicate lab value SGOT , SGPT , GGT , alkaline phosphatase , serum bilirubin 1.5 time great upper limit normal ; 14 . Clinically significant ECG abnormality vital sign abnormality screen history unstable , severe , clinically significant cardiovascular disease ( e.g. , myocardial infarction within previous 6 month , unstable angina , cardiac failure , second/third degree atrioventricular block ) ; 15 . Subjects take unapproved prescription overthecounter medication ; concomitant medication must discuss approve sponsor prior enrollment ; 16 . A known hypersensitivity tasimelteon drug similar tasimelteon include melatonin ; 17 . Pregnant lactating female ; 18 . Inability swallow study medication whole ; 19 . Any sound medical reason determine clinical Investigator . Groups 1 2 ( renal impairment ) 1 . Subjects clinically significant abnormal finding , consistent clinical disease , upon physical examination , ECG , laboratory evaluation ; 2 . Evidence progressive renal disease within 4 week prior screen ; 3 . Acute renal failure nephrotic syndrome ; 4 . Current hematuria urologic origin ; 5 . Any significant change chronic treatment medication determine clinical Investigator . Group 3 ( healthy match control ) 1 . Use unapproved prescription medication within 1 month dose OTC medication within 14 day prior dose ; 2 . History presence impair renal function indicate abnormal ( &gt; ULN ) creatinine BUN value abnormal urinary constituent ( e.g. , albuminuria ) . 3 . A positive hepatitis C test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>End stage renal disease</keyword>
	<keyword>ESRD</keyword>
	<keyword>kidney disease</keyword>
	<keyword>renal impairment</keyword>
	<keyword>renal</keyword>
</DOC>